#Immune thrombocytopenia is considered an #antibody -mediated disease.

However, a number of features suggest alternative methods of #platelet 🩸 destruction, like CD8+ T cell clones studied by Dr. Nichola Cooper's team at Imperial Department of Immunology & Inflammation!

Blood Journal | bit.ly/3K5UhGF

Discovery of ITP was Epic

Dr William Harrington, a hematology fellow at WashU, injected blood from an ITP pt into himself

His plt count dropped immediately, and he was admitted to Barnes Hospital with epistaxis, gingival, rectal bleeding

1 week later his plt returned to normal

Good news for some #immunosuppressed #patients - #VROOM study showed #rheumatoid #arthritis patients stopped #methotrexate for 2 weeks they had #CovidVaccine antibody response.

Kudos to Taryn Youngstein for leading the Imperial NHS 💙 part of the trial

1/

bbc.co.uk/news/health-61…

Thank you

Thank you Imperial Health Charity 💙 for the tickets to V&A corporate evening, we loved it! A great team night out 🎭 #faberge #beatrixpotter #fashioningmasculinities

Efficacy, Safety, Viral Clearance and Antibody Response in those receiving Tocilizumab for COVID-19 pneumonia

Important and unique data not collected by the other large trials

sciencedirect.com/science/articl…

Nichola Cooper Sanjay Bhagani Siniša Savić and co Roche

Great collaboration with Emma Davenport, Nichola Cooper and Graham P Taylor, and shoutout to Katie L Burnham and Allison Maher who did most of the work!

⁦Nichola Cooper⁩ Back in venue, register now for ITP Update Day - Friday 6th May at hartleytaylor.co.uk/itp3-home/

You can download a copy for FREE of our highly regarded - Making the right choices in ITP management and care itpsupport.org.uk/index.php/en/h…

We are delighted to announce that the Royal College of Physicians have reviewed and endorsed the clinical content of our ITP shared decision-making toolkit. The toolkit can be downloaded at bit.ly/3nBA2pb or email [email protected] for a hard copy.”

Fostamatinib: Ruxolitinib: SoC in COVID-19 patients from admission.

Imperial College London Imperial NHS 💙 study now multi-site

NIHR Imperial BRC Imperial Department of Immunology & Inflammation

Plus Rigel Pharmaceuticals +ve top line data on primary safety end point with Fostamatinib in COVID-19 rigel.com/investors/news…

Full video here:

youtube.com/watch?v=u7NNix…

(No I don’t appear 😉)

Truly wonderful video of clinical research Imperial NHS 💙 Imperial Medicine #COVID19 research including our evidence based Treatment group.

Proud to be a small part of this: Hannah Pluthero 💙 Graham Cooke Mark Gilchrist Prof Liz Lightstone PhD FRCP FISN 🇬🇧🇮🇱🇺🇦💙💜 Nichola Cooper Anthony Gordon MATIS remap-cap

So is there any way we prevent this? Yes, there may be! We identified that the drug fostamatinib (Syk inhibitor) can specifically counteract all of these effects. This drug is now in Phase 3 clinical trials, after successful Phase 2: rigel.com/investors/news… 8/14

Reason #2: in severe COVID-19 patients, the Fc tail of anti-Spike IgG is aberrantly glycosylated (different sugar groups). For details see our previous study in Science Magazine: science.sciencemag.org/content/371/65… 7/14

Paper in Journal of Thrombosis and Haemostasis comparing 43 samples tested for VITT using 10 different assays. Clearly shows that you should be using a HIT ELISA assay. tinyurl.com/h688469s #VITT

MATIS trial protocol published as a structured summary out now here: rdcu.be/cizOz

AshWhittington Victoria Cornelius asad charania

Nikhil Vergis Nichola Cooper Rachel

Andrew James Innes 💙💛 Melanie T Almonte 💙🐿📚🌱 Taryn Youngstein

www2.mrc-lmb.cam.ac.uk/evolutionary-j…

$RIGL #news - Positive topline data shows #fostamatinib met the primary endpoint of safety in Phase 2 #clinicaltrial in hospitalized patients with #COVID19 - rigel.com/investors/news…

And now with the corrected link (thanks for pointing out David Lee, MD!): biorxiv.org/content/10.110…